Medincell News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.12.24	Medincell to Join the Euronext SBF 120 Index (Businesswire)
09.12.24	Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement (Businesswire)
06.11.24	Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3 (Businesswire)
04.11.24	Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241 (Businesswire)
23.09.24	Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia (Businesswire)
23.09.24	Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris® (Businesswire)
05.09.24	Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI) (Businesswire)
03.09.24	Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline (Businesswire)
31.07.24	Medincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress (Businesswire)
08.05.24	Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia (Businesswire)
16.04.24	Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies (Businesswire)
08.04.24	Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria (Businesswire)
31.01.24	MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI) (Businesswire)
09.01.24	MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI) (Businesswire)
13.11.23	MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749) (Businesswire)
30.08.23	MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement (Businesswire)
04.05.23	MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada) (Businesswire)
24.01.23	Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK) (Businesswire)
05.01.23	MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population (Businesswire)
30.11.22	Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive (Businesswire)
23.11.22	France : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments (Businesswire)
07.11.22	MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement (Businesswire)
13.09.22	MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission (Businesswire)
05.09.22	MedinCell Secures Additional 20 Million Euros Financing With the European Investment Bank (EIB) (Businesswire)
29.08.22	Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology (Businesswire)
17.08.22	An Impact Company Committed to Improving the Health of Patients Worldwide, MedinCell Publishes Its 2021-2022 ESG Annual Report (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swisscom	581.00	2.74 %	K V
Swiss Re	148.10	1.26 %	K V
Zurich Insur Gr	563.60	1.26 %	K V
Swiss Life Hldg	853.60	0.92 %	K V
Geberit	629.00	0.80 %	K V
Lonza Grp	565.60	-1.12 %	K V
Alcon	71.00	-1.14 %	K V
CieFinRichemont	131.70	-1.27 %	K V
Sika	190.00	-1.35 %	K V
Logitech Intl	74.66	-1.94 %	K V

Medincell Aktie VALOR 1633005 / ISIN FR0004065605

Nachrichten zu Medincell SA Reg S

Aktien Top/Flop

Meistgelesene Nachrichten